Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Cash (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Change in Cash for 14 consecutive years, with -$14.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 23740.98% year-over-year to -$14.4 million, compared with a TTM value of $2.8 million through Dec 2025, up 198.96%, and an annual FY2025 reading of $2.8 million, up 198.96% over the prior year.
  • Change in Cash was -$14.4 million for Q4 2025 at Heron Therapeutics, down from $26.6 million in the prior quarter.
  • Across five years, Change in Cash topped out at $131.4 million in Q2 2021 and bottomed at -$69.0 million in Q4 2021.
  • Average Change in Cash over 5 years is -$3.8 million, with a median of -$6.4 million recorded in 2023.
  • The sharpest move saw Change in Cash skyrocketed 1069.87% in 2023, then crashed 23740.98% in 2025.
  • Year by year, Change in Cash stood at -$69.0 million in 2021, then soared by 49.19% to -$35.1 million in 2022, then surged by 82.37% to -$6.2 million in 2023, then surged by 100.99% to $61000.0 in 2024, then plummeted by 23740.98% to -$14.4 million in 2025.
  • Business Quant data shows Change in Cash for HRTX at -$14.4 million in Q4 2025, $26.6 million in Q3 2025, and -$2.8 million in Q2 2025.